Logo image of NTEC

Intec Parent Inc (NTEC) Stock Fundamental Analysis

USA - NASDAQ:NTEC -

9.63
-1.37 (-12.48%)
Last: 8/3/2021, 8:09:11 PM
9.9
+0.27 (+2.8%)
After Hours: 8/3/2021, 8:09:11 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NTEC. NTEC was compared to 534 industry peers in the Biotechnology industry. The financial health of NTEC is average, but there are quite some concerns on its profitability. NTEC is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NTEC has reported negative net income.

1.2 Ratios

Industry RankSector Rank
ROA -83.12%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NTEC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

5

2. Health

2.1 Basic Checks

NTEC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -18.11, we must say that NTEC is in the distress zone and has some risk of bankruptcy.
NTEC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.11
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 2.34 indicates that NTEC has no problem at all paying its short term obligations.
NTEC has a Quick Ratio of 2.34. This indicates that NTEC is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 2.34
Quick Ratio 2.34

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 80.45% over the past year.
EPS 1Y (TTM)80.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 9.23% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y174.75%
EPS Next 2Y17.79%
EPS Next 3Y18.23%
EPS Next 5Y9.23%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NTEC Yearly Revenue VS EstimatesNTEC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2019 2021 5M 10M 15M 20M 25M
NTEC Yearly EPS VS EstimatesNTEC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NTEC. In the last year negative earnings were reported.
Also next year NTEC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTEC Price Earnings VS Forward Price EarningsNTEC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.19
NTEC Per share dataNTEC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

NTEC's earnings are expected to grow with 18.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.79%
EPS Next 3Y18.23%

More info and screens

0

5. Dividend

5.1 Amount

NTEC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Intec Parent Inc

NASDAQ:NTEC (8/3/2021, 8:09:11 PM)

After market: 9.9 +0.27 (+2.8%)

9.63

-1.37 (-12.48%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners22.37%
Inst Owner Change-3.29%
Ins Owners514.2%
Ins Owner Change0%
Market Cap8.65M
Revenue(TTM)N/A
Net Income(TTM)-14487000
Analysts73.4
Price Target53.04 (450.78%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.76
P/tB N/A
EV/EBITDA 0.19
EPS(TTM)-3.44
EYN/A
EPS(NY)-2.5
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS12.63
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -83.12%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.34
Quick Ratio 2.34
Altman-Z -18.11
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y174.75%
EPS Next 2Y17.79%
EPS Next 3Y18.23%
EPS Next 5Y9.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

Intec Parent Inc / NTEC FAQ

What is the fundamental rating for NTEC stock?

ChartMill assigns a fundamental rating of 2 / 10 to NTEC.


What is the valuation status for NTEC stock?

ChartMill assigns a valuation rating of 3 / 10 to Intec Parent Inc (NTEC). This can be considered as Overvalued.


What is the profitability of NTEC stock?

Intec Parent Inc (NTEC) has a profitability rating of 1 / 10.


How financially healthy is Intec Parent Inc?

The financial health rating of Intec Parent Inc (NTEC) is 2 / 10.


Can you provide the expected EPS growth for NTEC stock?

The Earnings per Share (EPS) of Intec Parent Inc (NTEC) is expected to grow by 174.75% in the next year.